AGFB Agfa-Gevaert NV

Agfa-Gevaert Group and Dedalus sign share purchase agreement for sale of part of Agfa HealthCare’s IT business - Regulated information

Agfa-Gevaert Group and Dedalus sign share purchase agreement for sale of part of Agfa HealthCare’s IT business - Regulated information

Mortsel, Belgium – January 29, 2020 – 7.45 a.m. CET





As announced on December 2, 2019, the Board of Directors of the Agfa-Gevaert Group decided to enter into exclusive negotiations with Dedalus Holding S.p.A. to sell a part of Agfa HealthCare’s IT business (the “Business”). Today, both parties announce that they have signed the share purchase agreement, under which Dedalus S.p.A. would acquire 100% of the Business at an enterprise value of 975 million Euro, subject to regular working capital and net debt adjustments.

The transaction is subject to customary employees’ consultations, regulatory approvals and closing conditions. Both parties aim to close the transaction in the course of Q2 2020.

The Business consists of the Healthcare Information Solutions and Integrated Care activities, as well as the Imaging IT activities to the extent that these activities are tightly integrated into the Healthcare Information Solutions activities. This is the case mainly in the DACH region, France and Brazil.

End of message

About Agfa

The Agfa-Gevaert Group develops, manufactures and distributes an extensive range of analogue and digital imaging systems and IT solutions, mainly for the printing industry and the healthcare sector, as well as for specific industrial applications.

Agfa’s headquarters and parent company are located in Mortsel, Belgium.

The Agfa-Gevaert Group achieved a turnover of 2,247 million euro in 2018.

Contact:

Viviane Dictus

Director Corporate Communications

tel. 4

e-mail:



About Dedalus

Founded in 1990 in Florence, Dedalus, with over 2.000 employees, of which 1.200 in Italy, 550 in France and teams in 25 countries, is an international industrial group in the healthcare software industry specialized in the segment of diagnostic and clinical management solutions (HCIS), GPs and Primary care management, Interoperability and Population health management.

In 2016, the European Private Equity Fund Ardian acquired the 60% of the Dedalus Group boosting its international expansion and strengthening the R&D activities, which is now composed by more than 600 people.

Today, Dedalus exploits the full functional coverage of all ICT needs of any healthcare system, not limited to hospital systems, both public and private. In the last three years, Dedalus has totally renewed its offering, by addressing the state of art of paradigm in terms of technology and functionalities to anticipate the evolution of the clinical practice at the base of the change management of different healthcare system that in many countries are rethinking their organizations.

With more than 130 million euros of revenues in Italy, more than 60 million euros in France and globally more than 210 million euros, Dedalus is one of the leading global players in the sector and holds a leading position in Europe.

Contact:

Elisabetta Natali,

Communication Director

Attachment

EN
29/01/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Agfa-Gevaert NV

 PRESS RELEASE

Agfa announces additional measures to adjust the cost base of its trad...

Agfa announces additional measures to adjust the cost base of its traditional film activities to the reality in the market December 4, 2025 – 7:45 a.m. CET Regulated information Agfa announces additional measures to adjust the cost base of its traditional film activities to the reality in the market Mortsel, Belgium – December 4, 2025 – 7:45 a.m. CET Agfa today announced that it plans to implement additional measures to adjust the cost base of its traditional film activities to the accelerated global market decline. These measures are an extension to the plan that was announced in Novem...

 PRESS RELEASE

Agfa kondigt bijkomende maatregelen aan om de kostenbasis van zijn tra...

Agfa kondigt bijkomende maatregelen aan om de kostenbasis van zijn traditionele filmactiviteiten aan te passen aan de realiteit in de markt 4 december 2025 – 7:45 uur CET Gereglementeerde informatie Agfa kondigt bijkomende maatregelen aan om de kostenbasis van zijn traditionele filmactiviteiten aan te passen aan de realiteit in de markt Mortsel, België – 4 december 2025 – 7u45 Agfa kondigde vandaag aan dat het van plan is bijkomende maatregelen te nemen om de kostenbasis van zijn traditionele filmactiviteiten aan te passen aan de versnelde achteruitgang van de wereldwijde markten. Deze...

Guy Sips ... (+4)
  • Guy Sips
  • Jacob Mekhael
  • Livio Luyten
  • Wim Hoste
Guy Sips
  • Guy Sips

Agfa “Shrinking Business” & “Not-So-Growth Engines”

After three quarters, Agfa's 9M25 “Mature Business” (Radiology and Film DPC) sales dropped -6.4% y/y, driven by the accelerating medical film decline. While its “Growth Engines” (HealthCare IT, Digital Printing Solutions, Green Hydrogen Solutions) are intended to offset this, they also fell -0.9% y/y in the first nine months. We remain cautious (Hold; €1.0 Target Price) until strategic measures deliver and growth engines regain momentum.

Guy Sips
  • Guy Sips

Agfa Decline in medical film was even stronger than expected

Agfa's 3Q25 continued decline in medical film was even stronger than expected (€ 257m 3Q25 sales vs € 275m KBCS & CSS). Although the growth in cloud/SaaS in HealthCare IT all the divisions were below our and CSS forecasts as well on top-line as on REBIT-margins. The increase in Digital Printing & Chemicals was not sufficiently offsetting the impact from the decline in medical film and from cloud transition in HealthCare IT. Despite good cost control, REBIT decreased to -4m, mainly due to the d...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch